HRA005868
Title:
Screening and Identification of Personalized Neoantigens in Prostate Cancer
Release date:
2023-11-02
Description:
In this study, we intend to conduct whole-genome and transcriptome analysis of tumor tissues and blood samples from prostate cancer patients. Using bioinformatics methods, we aim to identify personalized, patient-specific neoantigens in order to better understand the immunological characteristics of the tumors. Furthermore, we will assess whether the selected neoantigens possess sufficient immunogenicity to elicit a strong immune response, thus contributing to the induction of a lasting anti-cancer immune response. This research is aimed at screening and identifying personalized neoantigens for prostate cancer, which will help in designing cancer vaccines and immunotherapy strategies for patients. It will also provide insights into the potential of immunotherapy in prostate cancer and offer crucial information for the development of future immunotherapeutic strategies.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
prostate cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
Prostate_neoantigen
Contact person:
Li shiliang
Email:
slli@hsc.ecnu.edu.cn
Description:
Manage WES- and RNA sequencing data from prostate cancer patients of this study
Individuals & samples
Submitter:   Li shiliang / slli@hsc.ecnu.edu.cn
Organization:   East China Normal University, Innovation Center for AI and Drug Discovery
Submission date:   2023-10-06
Requests:   1